

Reliability Findings from the Unified Global Training Program for the Brief Negative Symptoms Scale (BNSS)

Kirkpatrick B¹, Opler M^{2,3}, Strauss G⁴, Ahmed A⁵, Capodilupo G², Tatsumi K²

¹Dept. of Psychiatry & Behavioral Medicine, U. of Nevada-Reno, School of Medicine ²MedAvante-ProPhase, Inc. ³New York U. Medical Center ⁴Clinical Affective Neuroscience Laboratory, Georgia Psychiatric Risk Evaluation Program, U. of Georgia ⁵Psychotic Disorders Program, New York-Presbyterian/Westchester & Weill Cornell School of Medicine University Medical Center

BACKGROUND


- The Brief Negative Symptom Scale (BNSS) grew out of a recommendation from the NIMH-sponsored Consensus Development Conference on Negative Symptoms¹. The BNSS consists of 13 items organized into six subscales² and is rated based on a semi-structured interview with prompts and clarifying questions.
- The BNSS was designed to measure negative symptoms reliably and efficiently, and to be practical for use in clinical treatment trials. Key characteristics of the BNSS are that it: (i) is brief, consisting of only 13 items that can be rated in a 10- to 15-minute interview; (ii) has a concise manual with a semi-structured interview guide; (iii) is written clearly and simply; (iv) covers all five of the NIMH Consensus Conference domains; and (v) has good separation of the two dimensions thought to underlie negative symptoms (expressivity and anhedonia/amotivation/asociality)³.
- Reliability and other psychometric properties of psychiatric rating scales require careful evaluation across languages and cultures to prove their suitability for use in global clinical trials which require additional focus on the role of culture. This will help ensure that data can be properly interpreted across countries and regions to be pooled for analysis. The literature on this issue shows consistently that the expression of the same phenomena differs substantially across cultures⁴.
- Cross-cultural issues in assessment are particularly relevant in schizophrenia research⁵. Despite this, certain phenomenological structures are highly conserved, as seen in factor analyses of negative symptoms⁶. The BNSS has consistently demonstrated construct validity pertaining to avolition, anhedonia, and emotional expressivity⁷. Further, global studies of the BNSS have consistently demonstrated excellent internal consistency and validity with other negative symptom scales⁸, and recent research also reported that the BNSS is sensitive to drug effects, with effect sizes comparable to established scales².
- The BNSS has been translated and tested in German, Italian, Russian, Polish, Japanese, Turkish, Spanish, French, Danish, Chinese, Norwegian, Dutch, Portuguese, and Korean⁹.

CONCLUSION / SUMMARY

- Raters from different countries may perceive and evaluate the symptomatology of schizophrenia differently due to differences in expression at the patient level, perception and interpretation among clinicians, and other contextual factors⁵. To minimize the impact of cross-cultural effects, it is important to select and use a rating scale that reliably evaluates symptom severity and change across contexts.
- In this study, the BNSS achieved overall good-to-excellent inter-rater reliability among raters from different countries and cultures. The Asociality subscale showed comparatively lower reliability, suggesting there is a need for additional work to improve training, not only for the scale overall, but also for each subscale.
- The findings suggest that the BNSS is optimal for use in global clinical trials and further confirms that the BNSS is a valid and reliable negative symptom rating scale. Further study is warranted to investigate the cause of variability in Asociality, coupled with enhanced training and development of adjunctive strategies to improve inter-rater reliability across all subscales of the BNSS.

METHODS


Figure 1: DISTRIBUTION OF RATERS BY COUNTRY



RESULTS

- In 2016, a global unified rater training program for the BNSS was launched across academic and industry users. Using pooled data, an analysis on the BNSS reliability was conducted on raters participating in multi-site trials (n=253).
- In this analysis (Figure 2) the BNSS demonstrated excellent reliability overall, with ICC of .903 [95 percent CI: 0.807-0.965; F(12,228)=10.35, p<0.001], with some variation among individual subscales.
- The Anhedonia subscale showed excellent inter-rater reliability with an ICC of 0.973 [95 percent CI: 0.884-0.999; F(2,26)=36.78, p<0.001]. When combining Anhedonia and item 4 for subjective distress, the ICC fell to 0.924 [95 percent CI: 0.741-0.995; F(3,51)=13.09, p<0.001].
- The Avolition subscale had a good ICC of .816 [95 percent CI: 0.088-1.000; F(1,19)=5.44, p=0.031] Blunted affect was similar at an ICC of 0.843 [95 percent CI: 0.362-0.996; F(2,38)=6.377, p=0.004].
- The Alogia subscale also had a good inter-rater reliability with ICC of 0.893 [95 percent CI: 0.325-1.00; F(1,14)=9.33, p=0.009].
- One subscale, however, had a somewhat lower overall reliability, specifically the Asociality subscale with an ICC of 0.658, (F=2.923, p=0.104).

Figure 2: INTER-RATER RELIABILITY (ICC) OF BNSS RATERS (n=253)



REFERENCES

1. Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder, S.R. (2011). The brief negative symptom scale: psychometric properties. *Schizophrenia Bulletin*, 37, 300-305.
2. Kirkpatrick B, Saoud J B, Strauss G P, Ahmed AO, Tatsumi K, Opler M, ... & Davidson M. (2017). The brief negative symptom scale (BNSS): Sensitivity to treatment effects. *Schizophrenia Research*.
3. Strauss GP, Hong LE, Gold JM, Buchanan RW, McMahon RP, Keller WR, ... Kirkpatrick B. (2012b). Factor structure of the brief negative symptom scale. *Schizophrenia Research*, 142, 96-98.
4. Strauss GP, Keller WR, Buchanan RW, Gold JM, Fischer BA, McMahon RP, ... Kirkpatrick B. (2012a). Next-generation negative symptom assessment for clinical trials: validation of the brief negative symptom scale. *Schizophrenia Research*, 142, 88-92.
5. Kirmayer LJ. (2001). Cultural variations in the clinical presentation of depression and anxiety: implications for diagnosis and treatment. *Journal of Clinical Psychiatry*, 62 Suppl 13:22-8; discussion 29-30.
6. Aggarwal NK, Zhang XY, Stefanovics E, Chen DC, Xiu MH, Xu K, & Rosenheck RA. (2012) Rater evaluations for psychiatric instruments and cultural differences: the positive and negative syndrome scale in China and the United States. *Journal of Nervous and Mental Disorder*, 200(9):814-820.
7. Emsley RA, Niehaus DJ, Mbangi NI, Coosthuizen PP, Stein DJ, Maritz JS, ... Mallet J. (2001). The factor structure for positive and negative symptoms in South African Xhosa patients with schizophrenia. *Schizophrenia Research*, 47(2-3):149-57.
8. Strauss GP & Gold JM. (2016). A Psychometric Comparison of the Clinical Assessment Interview for Negative Symptoms and the Brief Negative Symptom Scale. *Schizophrenia Bulletin*. doi:10.1093/schbul/sbw046
9. Strauss GP, Vertinski M, Vogel SJ, Ringdahl EN, Allen DN. (2015). Negative symptoms in bipolar disorder and schizophrenia: a psychometric evaluation of the brief negative symptom scale across diagnostic categories. *Schizophrenia Research*, 170, 285-289.

